ClinicalTrials.gov
ClinicalTrials.gov Menu

Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01763164
Recruitment Status : Active, not recruiting
First Posted : January 8, 2013
Last Update Posted : March 21, 2018
Sponsor:
Information provided by (Responsible Party):
Array BioPharma

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Active, not recruiting
  Actual Primary Completion Date : December 2015
  Estimated Study Completion Date : July 31, 2018
  Certification/Extension First Submitted : September 30, 2016